Colicin V-treated Escherichia coli was inhibited in its capacity to carry out active transport of proline and was unable to generate a membrane potential. Colicin V also prevented membrane potential formation by isolated cytoplasmic membrane vesicles. We conclude that a primary effect of this colicin involves the cytoplasmic membrane as a target.
with an equal volume of 1.0 M potassium phosphate buffer (pH 6.6). The sample was next'passed over a hydrophobic column (5 ml of phenyl-Sepharose CL-4B; Sigma Chemical Co.) which had been equilibrated with 0.5 M potassium phosphate buffer (pH 6.6). Elution of the colicin was by application of a step-wise gradient consisting of 15-ml washes of 0.5, 0.25, 0.125, 0.0625, and 0.03125 M potassium phosphate buffer (pH 6.6). Activity eluted at 0.0625 M potassium phosphate and was determined by the spot-test * Corresponding author. dilution assay (14) . This preparation was not pure; analysis by high-pressure liquid chromatography (mentioned below) revealed that it contained many components. Because none of the systems tried led to the elution of substantial activity, we were unable to estimate the upper limit of purity obtained. Unfortunately, our efforts to further purify this material by several high-pressure liquid chromatography systems, including gel permeation on a Waters I-60 column, reverse-phase chromatography (Waters C18 Bondapak) with a variety of solvents, or ion-exchange chromatography (Waters Protein-Pak DEAE 5pw) have been unsuccessful. Throughout this paper, the concentration of partially purified colicin V is presented in terms of'protein concentration (15) .
Initial experiments showed that colicin V inhibited the incorporation of exogenously added [3H]proline into cellular protein (data not shown). To ascertain whether this finding reflected an effect of the colicin on active transport, we examined the ability of treated cells to take up [3H]proline into chloramphenicol-treated cells. Cells which had been treated with colicin V 10 min before the addition of proline were drastically diminished in their ability to transport the amino acid, relative to the control untreated culture (Fig. 1) . The addition of the colicin to cells which had accumulated proline for 17.5 min led to substrate efflux (Fig. 1) .
To determine whether the effect of colicin V on proline transport resulted from a specific inhibition of active transport or from a more generalized disruption of membrane integrity, we examined its effect on the accumulation of amethylglucoside, which is a substrate of the phosphoenolpyruvate phosphotransferase system and whose accumulation is not directly coupled to the transmembrane proton motive force (20) . Addition of colicin V to cells which had accumulated this substrate induced a dramatic increase in the amount of substrate accumulated (Fig. 2) . As expected, a similar effect was observed in the case of colicin Ia-treated cells (6) . In contrast, neither colicin had an effect on an isogenic strain carrying a mutation in the structural gene for the colicin I receptor. Such cir mutants are resistant to colicins la and Tb and insensitive to colicin V (3, 4). Finally, it was shown that substrate accumulation was stimulated by colicin Ta, but not by colicin V in a strain harboring a plasmid which contains the cloned colicin V immunity gene. The apparent, less-dramatic effect of colicin Ta on the colicin Vimmune strain (Fig. 2C ) when compared with the effect on the strain harboring neither plasmid ( Fig. 2A) 11.5 Ci/mol) was added. At the indicated times, 0.4-ml portions were withdrawn, and the amount of proline which had accumulated in the cells was determined (6) . The data have not been corrected for the zero time sampling. When used, colicin was added to a final concentration of 0.4 ,ug/ml. Symbols: 0, control; U, colicin added at -10 min; 0, colicin added at 17.5 min.
higher levels of stimulation by colicin Ia in these strains in other experiments. These results show that the inhibition of active transport by colicin V does not result from a generalized leakiness of the cellular membrane.
Since it is known that agents which disrupt the proton motive force enhance a-methylglucoside accumulation (18) , a similar finding in the case of this colicin suggested a similar effect on cell metabolism. To examine this possibility, we determined the capacity of colicin V-treated cells to generate a membrane potential by assaying their capacity to accumulate the membrane permeant, triphenylmethylphosphonium cation (TPMP+) (19) . Treatment of sensitive cells with either colicin V or the uncoupler, carbonyl cyanide m-chlorophenylhydrazone, prevented the generation of a membrane potential (Fig. 3A ). An isogenic strain carrying a plasmid containing the cloned colicin V immunity gene was fully able to generate a membrane potential after treatment with colicin V, but was inhibited by colicin Ta (Fig. 3B) . In contrast, a strain carrying a plasmid containing the cloned colicin la immunity gene was able to generate a membrane potential after treatment with colicin Ta but not after treatment with colicin V.
We have previously described conditions whereby it has been possible to demonstrate the in vitro action of colicin Ta and lb on membrane vesicles prepared from sensitive or resistant (receptorless) strains (24, 27) . These experiments and those with liposomes and planar membranes (10, 22, 25, 26) have led to the conclusion that the primary target of colicins which are known to disrupt the membrane potential in whole cells is the cytoplasmic membrane. We, therefore, examined the effect of colicin V on the ability of membrane vesicles prepared from sensitive and insensitive (cir) strains to generate a membrane potential. Addition of colicin V to vesicles prepared from either strain inhibited ascorbatephenazine methosulfate-driven TPMP+ uptake (Fig. 4) . These results taken together with our in vivo observations strongly suggest that the primary target of colicin V is the cytoplasmic membrane. It should be noted that a suggestion has been made that colicin V inhibits cells by affecting the cellular energy supply (13) . That vesicles prepared from colicin V-insensitive cells were sensitive to the colicin in vitro was not surprising in view of previous studies dealing with other colicins (12) . Although the cir gene product is known to be the outer membrane receptor for colicin Ia and lb (3) , its exact role in ,ffect of colicins V and la on TPMP+ accumulation in whole cells. Cells grown to a 100 Klett units as described in the legend to Fig. 1 were treated with colicin for 15 min at 25°C, harvested, treated with EDTA as previously described (27) , and finally washed and resuspended in 1/10 of the original culture volume in 50 mM potassium phosphate buffer (pH 6.6). At zero time, potassium ascorbate (20 mM) and phenazine methosulfate (0.1 mM) were added, followed immediately by [3H]TPMP+ (0.4 mM, 2.5 Ci/mol). This mixture was incubated at 25°C under an atmosphere of pure 02. At the indicated times, samples were removed, and the amount of accumulated TPMP+ was determined (27) There is now much evidence that those colicins which act by depolarizing the bacterial energy transducing membrane in vivo are able to form aqueous channels in both closed liposomes as well as in planar membranes (12) . In the case of colicin V, however, we have found that under conditions in which we can demonstrate colicin Ta-or El-induced leakiness of asolectin liposomes toward phosphate or chloride, colicin V has no effect (C.-C. Yang, J. Konisky, V. L. Davidson, and W. A. Cramer, unpublished data). It remains to be established whether these differences reflect a real difference in the in vivo mode of action.
